Doehn Christian, Böhmer Torsten, Jocham Dieter
University of Lübeck Medical School, Department of Urology, Lübeck, Germany.
Curr Opin Mol Ther. 2005 Oct;7(5):511-9.
Onyvax is developing Onyvax-P, an allogeneic whole-cell vaccine, for the potential treatment of prostate cancer. The vaccine is currently undergoing phase II clinical trials.
